Vertex Pharmaceuticals (VRTX) said Monday that the European Commission has expanded the label for Kaftrio in cystic fibrosis to include patients 2 years and older who have at least one non-class I mutation in the cystic fibrosis conductance regulator gene.
The company said around 4,000 cystic fibrosis patients in the European Union are now eligible to receive the medicine.
Kaftrio, or ivacaftor/tezacaftor/elexacaftor, is administered in combination with ivacaftor to treat cystic fibrosis patients.
Vertex said eligible patients in Austria, Denmark, Ireland, Norway, Sweden and Germany are expected to have access to Kaftrio "shortly."
Price: 469.03, Change: -5.59, Percent Change: -1.18
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。